Lymphadenectomy in surgery for cancers of the stomach and esophagus;La chirurgie ganglionnaire dans les cancers de l'œsophage et de l'estomac

Journal de Chirurgie

Volumn 145, Issue HS4, 2008, Pages

  Mariette, C ^a   Piessen, G ^a   Vons, C ^b  

^a LILLE UNIVERSITY HOSPITAL   (France)

^b HÔPITAL JEAN VERDIER   (France)

Author keywords

Cancer; Lymph node; Lymphadenectomy; Oesophagus; Stomach; Surgery

Indexed keywords

CANCER STAGING; ESOPHAGUS RESECTION; ESOPHAGUS TUMOR; EVIDENCE BASED MEDICINE; GASTRECTOMY; HUMAN; LYMPHADENECTOMY; METHODOLOGY; MORTALITY; PATHOLOGY; PRACTICE GUIDELINE; PROGNOSIS; RANDOMIZED CONTROLLED TRIAL; REVIEW; STOMACH TUMOR; SURVIVAL;

ESOPHAGEAL NEOPLASMS; ESOPHAGECTOMY; EVIDENCE-BASED MEDICINE; GASTRECTOMY; HUMANS; LYMPH NODE EXCISION; NEOPLASM STAGING; PRACTICE GUIDELINES AS TOPIC; PROGNOSIS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; STOMACH NEOPLASMS; SURVIVAL ANALYSIS;

EID: 58149127814     PISSN: 00217697     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0021-7697(08)74718-5     Document Type: Article

References (99)

1. Isono K, Sato H, Nakayama K. Results of a nationwide study on the three-field lymph node dissection of esophageal cancer. Oncology 1991;48:411-420.
2. Akiyama H, Tsurumaru M, Udagawa H, Kajiyama Y. Radical lymph node dissection for cancer of the thoracic esophagus. Ann Surg 1994;220:364-372.
3. Lerut T, Coosemans W, Decker G, et al. Surgical techniques. J Surg Oncol 2005;92:218-229.
4. Fumagalli U and Panel of experts. Resective surgery for cancer of the thoracic esophagus. Results of a Consensus Conference at the VIth World Congress of the International Society for Diseases of the Esophagus. Dis Esophagus 1996;9 Suppl. 1, 30-38.
5. Moreno GE, Garcia GI, Pinto GA, et al. Results of transhiatal esophagectomy in cancer of the esophagus and other diseases. Hepatogastroenterology 1992;39:439-442.
6. Holscher AH, Bollschweiler E, Bumm R, Bartels H, Hofler H, Siewert JR. Prognostic factors of resected adenocarcinoma of the esophagus. Surgery 1995; 118: 845-855.
7. Johansson J, DeMeester TR, Hagen JA, et al. En bloc vs transhiatal esophagectomy for stage T3 N1 adenocarcinoma of the distal esophagus. Arch Surg 2004;139:627-631.
8. Hulscher JB, van Sandick JW, de Boer AG, et al. Extended transthoracic resection compared with limited transhiatal resection for adenocarcinoma of the esophagus. N Engl J Med 2002;347:1662-1669.
9. Mariette C, Taillier G, Van Seuningen I, Triboulet JP. Factors affecting postoperative course and survival after en bloc resection for esophageal carcinoma. Ann Thorac Surg 2004;78:1177-1183.
10. Junginger T, Gockel I, Heckhoff S. A comparison of transhiatal and transthoracic resections on the prognosis in patients with squamous cell carcinoma of the esophagus. Eur J Surg Oncol 2006;32:749-755.
11. Fujita H, Kakegawa T, Yamana H, et al. Mortality and morbidity rates, postoperative course, quality of life, and prognosis after extended radical lymphadenectomy for esophageal cancer. Comparison of three-field lymphadenectomy with two-field lymphadenectomy. Ann Surg 1995;222:654-662.
12. Altorki N, Kent M, Ferrara C, Port J. Three-field lymph node dissection for squamous cell and adenocarcinoma of the esophagus. Ann Surg 2002;236:177-183.
13. Lerut T, Nafteux P, Moons J, et al. Three-field lymphadenectomy for carcinoma of the esophagus and gastroesophageal junction in 174 R0 resections: impact on staging, disease-free survival, and outcome: a plea for adaptation of TNM classification in upper-half esophageal carcinoma. Ann Surg 2004;240:962-972.
14. Peyre C, Hager J, de Meester S et al. The number of lymph nodes removed predicts survival in esophageal cancer: An international study of the impact of extent of surgical resection. Ann Surg 2008;248:549-556.
15. Mariette C, Piessen G, Briez N, Triboulet JP. The number of metastatic lymph nodes and the ratio between metastatic and examined lymph nodes are independent prognostic factors in esophageal cancer regardless of neoadjuvant chemoradiation or lymphadenectomy extent. Ann Surg 2008;247:365-371.
16. Eloubeidi MA, Desmond R, Arguedas MR, Reed CE, Wilcox CM. Prognostic factors for the survival of patients with esophageal carcinoma in the U.S.: the importance of tumor length and lymph node status. Cancer 2002;95:1434-1443.
17. Roder JD, Busch R, Stein HJ, Fink U, Siewert JR. Ratio of invaded to removed lymph nodes as a predictor of survival in squamous cell carcinoma of the oesophagus. Br J Surg 1994;81:410-413.
18. Tachibana M, Dhar DK, Kinugasa S, et al. Esophageal cancer with distant lymph node metastasis: prognostic significance of metastatic lymph node ratio. J Clin Gastroenterol 2000;31:318-322.
19. Wijnhoven BP, Tran KT, Esterman A, Watson DI, Tilanus HW. An evaluation of prognostic factors and tumor staging of resected carcinoma of the esophagus. Ann Surg 2007;245:717-725.
20. Hulscher JB, Van Sandick JW, Offerhaus GJ, Tilanus HW, Obertop H, Van Lanschot JJ. Prospective analysis of the diagnostic yield of extended en bloc resection for adenocarcinoma of the oesophagus or gastric cardia. Br J Surg 2001;88:715-719.
21. Sasako M, Sano T, Yamamoto S, et al. Left thoracoabdominal approach versus abdominal-transhiatal approach for gastric cancer of the cardia or subcardia: a randomised controlled trial. Lancet Oncol 2006;7:644-651.
22. Wu PC, Posner MC. The role of surgery in the management of oesophageal cancer. Lancet Oncol 2003;4:481-488.
23. Law S, Wong J. Therapeutic options for esophageal cancer. J Gastroenterol Hepatol 2004;19:4-12.
24. Goldminc M, Maddern G, Le Prise E, Meunier B, Campion JP, Launois B. Oesophagectomy by a transhiatal approach or thoracotomy: a prospective randomized trial. Br J Surg 1993;80:367-370.
25. Chu KM, Law SY, Fok M, Wong J. A prospective randomized comparison of transhiatal and transthoracic resection for lower-third esophageal carcinoma. Am J Surg 1997;174:320-324.
26. Jacobi CA, Zieren HU, Muller JM, Pichlmaier H. Surgical therapy of esophageal carcinoma: the influence of surgical approach and esophageal resection on cardiopulmonary function. Eur J Cardiothorac Surg 1997;11:32-37.
27. Rindani R, Martin CJ, Cox MR. Transhiatal versus Ivor-Lewis oesophagectomy: is there a difference? Aust N Z J Surg 1999;69:187-194.
28. Hulscher JB, Tijssen JG, Obertop H, van Lanschot JJ. Transthoracic versus transhiatal resection for carcinoma of the esophagus: a meta-analysis. Ann Thorac Surg 2001;72:306-313.
29. Hulscher JB, van Lanschot JJ. Individualised surgical treatment of patients with an adenocarcinoma of the distal oesophagus or gastro-oesophageal junction. Dig Surg 2005;22:130-134.
30. Omloo JM, Lagarde SM, Hulscher JB, et al. Extended transthoracic resection compared with limited transhiatal resection for adenocarcinoma of the mid/distal esophagus: five-year survival of a randomized clinical trial. Ann Surg 2007;246:992-1000.
31. Feith M, Stein HJ, Siewert JR. Adenocarcinoma of the esophagogastric junction: surgical therapy based on 1602 consecutive resected patients. Surg Oncol Clin N Am 2006;15:751-764.
32. Siewert JR, Stein HJ, Feith M, Bruecher BL, Bartels H, Fink U. Histologic tumor type is an independent prognostic parameter in esophageal cancer: lessons from more than 1,000 consecutive resections at a single center in the Western world. Ann Surg 2001;234:360-367.
33. Siewert JR, Feith M, Stein HJ. Biologic and clinical variations of adenocarcinoma at the esophago-gastric junction: relevance of a topographic-anatomic subclassification. J Surg Oncol 2005;90:139-146.
34. Kodera Y, Yamamura Y, Shimizu Y, et al. Adenocarcinoma of the gastroesophageal junction in Japan: relevance of Siewert's classification applied to 177 cases resected at a single institution. J Am Coll Surg 1999;189:594-601.
35. Fein M, Fuchs KH, Ritter MP, et al. Application of the new classification for cancer of the cardia. Surgery 1998; 124: 707-13.
36. Martin RC 2nd, Jaques DP, Brennan MF, Karpeh M. Achieving RO resection for locally advanced gastric cancer: is it worth the risk of multiorgan resection? J Am Coll Surg 2002;194:568-577.
37. Sauvanet A, Mariette C, Thomas P, et al. Mortality and morbidity after resection for adenocarcinoma of the gastroesophageal junction: predictive factors. J Am Coll Surg 2005;201:253-262.
38. Tachibana M, Kinugasa S, Yoshimura H, Dhar DK, Nagasue N. Extended esophagectomy with 3-field lymph node dissection for esophageal cancer. Arch Surg 2003;138:1383-1389.
39. Mariette C, Balon JM, Piessen G, Fabre S, Van Seuningen I, Triboulet JP. Pattern of recurrence following complete resection of esophageal carcinoma and factors predictive of recurrent disease. Cancer 2003;97:1616-1623.
40. Kato H, Tachimori Y, Watanabe H, Igaki H, Nakanishi Y, Ochiai A. Recurrent esophageal carcinoma after esophagectomy with three-field lymph node dissection. J Surg Oncol 1996;61:267-272.
41. Nishimaki T, Suzuki T, Kanda T, Obinata I, Komukai S, Hatakeyama K. Extended radical esophagectomy for superficially invasive carcinoma of the esophagus. Surgery 1999;125:142-147.
42. Nishihira T, Hirayama K, Mori S. A prospective randomized trial of extended cervical and superior mediastinal lymphadenectomy for carcinoma of the thoracic esophagus. Am J Surg 1998;175:47-51.
43. Nagatani S, Shimada Y, Kondo M, et al. A strategy for determining which thoracic esophageal cancer patients should undergo cervical lymph node dissection. Ann Thorac Surg. 2005;80:1881-1886.
44. Altorki NK. Three-field lymphadenectomy for esophageal cancer. Chest Surg Clin N Am 2000;10:553-560.
45. Baba M, Aikou T, Yoshinaka H, et al. Long-term results of subtotal esophagectomy with three-field lymphadenectomy for carcinoma of the thoracic esophagus. Ann Surg 1994;219:310-316.
46. Nishimaki T, Suzuki T, Tanaka Y, Nakagawa S, Aizawa K, Hatakeyama K. Evaluating the rational extent of dissection in radical esophagectomy for invasive carcinoma of the thoracic esophagus. Surg Today 1997;27:3-8.
47. Tachibana M, Kinugasa S, Yoshimura H, et al. En-bloc esophagectomy for esophageal cancer. Am J Surg 2004;188:254-260.
48. Skinner DB. En bloc resection for neoplasms of the esophagus and cardia. J Thorac Cardiovasc Surg 1983;85:59-70.
49. Altorki N, Skinner D. Should en bloc esophagectomy be the standard of care for esophageal carcinoma? Ann Surg 2001;234:581-587.
50. Collard JM, Otte JB, Fiasse R, et al. Skeletonizing en bloc esophagectomy for cancer. Ann Surg 2001;234:25-32.
51. Hagen JA, DeMeester SR, Peters JH, Chandrasoma P, DeMeester TR. Curative resection for esophageal adenocarcinoma: analysis of 100 en bloc esophagectomies. Ann Surg 2001;234:520-530.
52. Lerut T, De Leyn P, Coosemans W, Van Raemdonck D, Scheys I, LeSaffre E. Surgical strategies in esophageal carcinoma with emphasis on radical lymphadenectomy. Ann Surg 1992;216:583-590.
53. Collard JM. Exclusive radical surgery for esophageal adenocarcinoma. Cancer 2001;91:1098-1104.
54. Hagen JA, Peters JH, DeMeester TR. Superiority of extended en bloc esophagogastrectomy for carcinoma of the lower esophagus and cardia. J Thorac Cardiovasc Surg 1993;106:850-858.
55. Hulscher JB, van Sandick JW, Tijssen JG, Obertop H, van Lanschot JJ. The recurrence pattern of esophageal carcinoma after transhiatal resection. J Am Coll Surg 2000;191:143-148.
56. Siewert JR, Bittcher K, Stein HJ, et al. Relevant prognostic factors in gastric cancer: ten-year results of the German Gastric cancer Study. Ann Surg 1998; 228: 449-461.
57. Bozzetti F, Bonfanti G, Morabito T, et al. A multifactorial approach for the prognosis of patients with carcinoma of the stomach after curative resection. Surg Gynecol Obstet 1986;162:229-234.
58. Hohenberger P, Gretschel S. Gastric cancer. Lancet 2003;362:305-315.
59. Dicken BJ, Bigam DL, Cass C, et al. Gastric adenocarcinoma: review and considerations for future directions. Ann Surg 2005;241:27-39.
60. Japanese Research Society for Stomach Cancer. General rules for gastric cancer study in surgery and pathology. Jpn J Surg 1981;16:127-139.
61. Elias D. Technique chirurgicale des curages ganglionnaires étendus (de type R2 et R3) pour adénocarcinomes gastriques. Ann Chir 1995;49:13-23.
62. Okajima K, Isozaki H. Splenectomy for treatment of gastric cancer: Japanese experience. World J Surg 1995;19:537-540.
63. Noda N, Sasako M, Yamaguchi N, Nakanishi Y. Ignoring small lymph nodes can be amajor cause of staging error in gastric cancer. Br J Surg 1998;85:831-834.
64. Sobin LH, Wittekind CH. International Union Against Cancer (UICC): TNM Classification of Malignant Tumors, 5th ed. New York: John Wiley and Sons; 2002.
65. Greene FL, Page DL, Fleming ID, et al. AJCC Cancer Staging Manual, 6th ed. New York: Springer-Verlag, 2002.
66. Bouvier AM, Haas O, Piard F, et al. How many nodes must be examined to accurately stage gastric adenocarcinomas? Results from a population based study. Cancer 2002;94:2862-2866.
67. Siewert JR, Böttcher K, Roder JD, Buxch R, Hermanek P, Meyer HJ and the GermanGastric Carcinoma Study Group. Prognostic relevance of systematic lymph node dissection ingastric carcinoma. Br J Surg 1993;80:1015-1018.
68. Keller E, Stützer H, Heitmann K et al. Lymph node staging in 872 patientswith carcinoma of the stomach and the presumed benefit of lymphadenectomy. German Stomach Cancer TNM Study Group. J Am Coll Surg 1994;178:8-46.
69. Bunt AMG, Hermans J, Smit VTHBM, et al. Surgical/pathologic-stage migrationconfounds comparisons of gastric cancer survival rates between Japan and westerncountries. J Clin Oncol 1995;13:19-25.
70. Feinstein AR, Sosin DM, Wells CK. The Will Rogers phenomenon. Stages migration and new diagnostic techniques as a source of misleading statistics for survival in cancer. N Engl J Med 1985;312:1604-1608.
71. Marchet A, Mocellin S, Ambrosi A, et al. Italian Research Group for Gastric Cancer (IRGGC). The ratio between metastatic and examined lymph nodes (N ratio) is an independent prognostic factor in gastric cancer regardless of the type of lymphadenectomy: results from an Italian multicentric study in 1853 patients. Ann Surg 2007;245:543-552.
72. Maruyama K. Quantitative statistical studies on lymph node metastasis of gastric carcinoma with references to its relationship with primary lesion and prognosis. J Jpn Surg Soc 1981;82:612-621.
73. Maruyama K, Gunven P, Okabayashi K, et al. Lymph node metastases for gastric cancer. General pattern in 1931 patients. Ann Surg 1989;210:596-601.
74. Maruyama K, Sasako M, Kinoshita T, et al. Surgical treatment for gastric cancer: the Japanese approach. Semin Oncol 1996; 23: 360-368.
75. Peeters KC, Hundahl SA, Kranenbarg EK, Hartgrink H, van de Velde CJ. Low Maruyama index surgery for gastric cancer: blinded reanalysis of the Dutch D1-D2 trial. World J Surg 2005;29:1576-1584.
76. Dent DM, Madden MV, Price SK. Randomized comparison of R 1 and R 2 gastrectomy for gastric carcinoma. Br J Surg 1988;75:110-112.
77. Robertson CS, Chung SCS, Woods SDS, et al. A prospective randomized trial comparing R1, subtotal gastrectomy with R 3 total gastrectomy for antral cancer. Ann Surg 1994; 220:176-182.
78. Cuschieri A, Fayers P, Fielding J, et al. Postoperative morbidity and mortality after D1 and D2 resections for gastric cancer: preliminary results of the MRC randomised controlled surgical trial. The Surgical Cooperative Group. Lancet 1996;347:995-999.
79. Cuschieri A, Weeden S, Fielding J, et al. Patient survival after D1 and D2 resections for gastric cancer: long-term results of the MRC randomized surgical trial. Surgical Co-operative Group. Br J Cancer 1999;79:1522-1530.
80. Bonenkamp JJ, Bunt AMG, van de Velde CJ, Sasako M, Boon MC. Radical lymphadenectomy for gastric cancer. A prospective randomized trial in the Netherlands. Surg Oncol Clin North Am 1993;2:443-458.
81. Bonenkamp JJ, Songun I, Hermans J, et al. Randomised comparison of morbidity after D1 and D2 dissection for gastric cancer in 996 Dutch patients. Lancet 1995;345:745-748.
82. Bonenkamp JJ, Hermans J, Sasako M, et al. Dutch Gastric Cancer Group. Extended lymph-node dissection for gastric cancer. N Engl J Med 1999;340:908-914.
83. Wu CW, Hsiung CA, Lo SS, Hsieh MC, Shia LT, Whang-Peng J. Randomized clinical trial of morbidity after D1 and D3 surgery for gastric cancer. Br J Surg 2004;91:283-287.
84. Wu CW, Hsiung CA, Lo SS, et al. Nodal dissection for patients with gastric cancer: a randomised controlled trial. Lancet Oncol 2006;7:309-315.
85. McCulloch P, Nita ME, Kazi H, Gama-Rodrigues J. Extended versus limited lymph nodes dissection technique for adenocarcinoma of the stomach. Cochrane Database of Systematic Reviews 2003;4:CD001964.
86. Parikh D, Johnson M, Chagla L, Lowe D, McCulloch P. D2 gastrectomy: lessons from a prospective audit of the learning curve. Br J Surg 1996;83:1595-1599.
87. Wu CW, Chang IS, Lo SS, et al. Complications following D3 gastrectomy: post hoc analysis of a randomized trial. World J Surg 2006;30:12-16.
88. Sano T, Sasako M, Yamamoto S, et al. Gastric cancer surgery: morbidity and mortality results from a prospective randomized controlled trial comparing D2 and extended para-aortic lymphadenectomy - Japan Clinical Oncology Group study 9501. J Clin Oncol 2004;22:2767-2773.
89. Kodera Y, Yamamura Y, Shimizu Y, et al. Metastatic gastric lymph node rate is a significant prognostic factor for respectable stage IV stomach cancer. J Am Coll Surg 1997;185:65-69.
90. Yonemura Y, Wu CC, Fukushima N, et al. East Asia Surgical Oncology Group. Operative morbidity and mortality after D2 and D4 extended dissection for advanced gastric cancer: a prospective randomized trial conducted by Asian surgeons. Hepatogastroenterology 2006;53:389-394.
91. Kulig J, Popiela T, Kolodziejczyk P, Sierzega M, Szczepanik A; Polish Gastric Cancer Study Group. Standard D2 versus extended D2 (D2+) lymphadenectomy for gastric cancer: an interim safety analysis of a multicenter, randomized, clinical trial. Am J Surg 2007;193:10-15.
92. Csendes A, Burdiles P, Rojas J, Braghetto I, Diaz JC, Maluenda F. A prospective randomized study comparing D2 total gastrectomy versus D2 total gastrectomy plus splenectomy in 187 patients with gastric carcinoma. Surgery 2002;131:401-407.
93. Yu W, Choi GS, Chung HY. Randomized clinical trial of splenectomy versus splenic preservation in patients with proximal gastric cancer. Br J Surg 2006;93:559-563.
94. Ishikawa S, Togashi A, Inoue M, et al. Indications for EMR/ESD in cases of early gastric cancer: relationship between histological type, depth of wall invasion, and lymph node metastasis. Gastric Cancer 2007;10:35-38.
95. Lo SS, Wu CW, Chen JH, et al. Surgical results of early gastric cancer and proposing a treatment strategy. Ann Surg Oncol 2007;14:340-347.
96. Aurello P, D'Angelo F, Rossi S, et al. Classification of lymph node metastases from gastric cancer: comparison between N-site and N-number systems. Our experience and review of the literature. Am Surg 2007;73:359-366.
97. Kunisaki C, Akiyama H, Nomura M, et al. Lymph node status in patients with submucosal gastric cancer. Ann Surg Oncol 2006;13:1364-1371.
98. Okabayashi T, Kobayashi M, Sugimoto T, Okamoto K, Hokimoto N, Araki K. Clinicopathological investigation of early gastric carcinoma; is less invasive surgery right for early gastric carcinoma? Hepatogastroenterology 2007;54:609-612.
99. Baba H, Maehara Y, Okuyama T, et al. Lymph node metastasis and macroscopic features in early gastric cancer. Hepatogastroenterology 1994;41:380-383.